Leqvio (Inclisiran) Cost in Hawaii 2026: Cash Price, Insurance, Medicaid, and Compounding

What Is Inclisiran and Why Is It Prescribed?

Inclisiran is a first-in-class small interfering RNA (siRNA) that silences PCSK9 synthesis in hepatocytes, causing sustained LDL receptor upregulation and durable LDL-cholesterol lowering with only two injections per year after a loading phase. The FDA approved Leqvio (Novartis) in December 2021 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy. [1]

The ORION-10 phase 3 trial (N=1,561, statin-treated patients with ASCVD) demonstrated a 52.3% placebo-adjusted reduction in LDL-C from baseline at day 510. [2] The companion ORION-11 trial (N=1,617 patients with ASCVD or ASCVD risk equivalents) showed a 49.9% placebo-adjusted LDL-C reduction at day 510. [2] Both trials reported injection-site reactions in roughly 2.6% of participants, which resolved without sequelae.

The American College of Cardiology and American Heart Association 2018 Cholesterol Guideline identifies PCSK9 inhibition as a Class IIa recommendation for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy. [3] Inclisiran fits that same clinical niche but offers the unique advantage of pharmacy-dispensed, twice-yearly subcutaneous dosing rather than every-2-week or monthly self-injection.

Leqvio List Price in Hawaii in 2026

The Novartis wholesale acquisition cost for Leqvio is approximately $3,240 per year in 2026, which pharmacy benefit databases commonly express as roughly $540 per 30-day equivalent. [4]

Hawaii patients paying fully out of pocket would face this list price at retail chain pharmacies such as Longs Drugs (CVS) and Safeway Pharmacy across Oahu, Maui, and the Big Island. No Hawaii-specific rebate or state drug pricing program currently reduces this list price at the cash register for Leqvio.

For context, the two older PCSK9 monoclonal antibodies, evolocumab (Repatha) and alirocumab (Praluent), carry similar annual list prices of roughly $6,400 to $6,700 per year, making inclisiran's twice-yearly dosing schedule a modest list-price advantage on a per-dose basis even before insurance negotiations. [5]

Hawaii Medicaid Coverage for Leqvio

Hawaii Medicaid (Med-QUEST) does not cover Leqvio as of 2026. [6] Prior authorization requests submitted through Med-QUEST managed care plans, including AlohaCare, HMSA, Kaiser Permanente Hawaii, and 'Ohana Health Plan, have not been approved for inclisiran because the drug lacks a Medicaid rebate agreement adequate for plan formulary placement under current Hawaii DHS guidance.

Patients enrolled in Hawaii Medicaid who require aggressive LDL-C lowering and cannot afford cash-pay inclisiran have several alternatives worth discussing with their prescriber. Evolocumab biosimilar (Repatha), while not universally covered either, has been approved under some Med-QUEST managed care formularies with prior authorization. Generic ezetimibe 10 mg is broadly covered and produces an additional 18 to 20% LDL-C reduction on top of statin therapy per the IMPROVE-IT trial (N=18,144). [7] Bempedoic acid (Nexletol) coverage through Med-QUEST varies by plan.

The ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD whose LDL-C level remains 70 mg/dL or higher while receiving maximally tolerated statin therapy, it is reasonable to add ezetimibe therapy." [3] Hawaii Medicaid patients may therefore build a multi-drug regimen around covered generics while awaiting inclisiran access.

Commercial Insurance and Prior Authorization in Hawaii

Most large commercial insurers operating in Hawaii, including HMSA (Blue Cross Blue Shield affiliate), Kaiser Permanente Hawaii, United Healthcare Hawaii, and Aetna, place Leqvio on specialty tier formularies requiring prior authorization. [8]

Typical prior authorization criteria across these plans include all of the following: a documented LDL-C at or above 70 mg/dL (for ASCVD patients) or at or above 100 mg/dL (for HeFH patients without clinical ASCVD); evidence of at least 90 days of maximally tolerated statin therapy, which may include a documented statin intolerance attestation; and a prescribing cardiologist or lipid specialist note confirming clinical indication. [9]

Approval rates for Leqvio prior authorization nationally have improved since 2022 as plans have established clearer criteria, though exact Hawaii-specific approval rates are not publicly published. Patients denied at initial review should request a peer-to-peer review with the plan's medical director; data from the ORION clinical program supporting 50% or greater LDL-C reduction, combined with the ACC's Class IIa recommendation, has supported successful appeals in many cases. [2][3]

Once approved, out-of-pocket cost under commercial insurance in Hawaii ranges from $0 (with the Novartis Savings Card) to a standard specialty-tier copay that averages $100 to $200 per injection depending on plan design.

How the Novartis Leqvio Savings Card Works

The Novartis Leqvio Savings Card (also called the Leqvio Patient Support Program) allows commercially insured, Medicare-ineligible patients to pay as little as $0 per dose. [10] The program covers the gap between insurance payment and the list price for eligible patients.

Key eligibility rules apply. Patients must have commercial insurance that covers Leqvio (even partially). Medicare Part D, Medicaid, and other government-funded insurance enrollees are explicitly ineligible. The card is processed at the time of dispensing or administration and can be activated at the program website. Annual benefit limits apply and are subject to change; the 2025 program capped at $16,000 per calendar year, which is sufficient to cover two to three injections at list price. [10]

Hawaii-based patients should activate the card before their first injection, because retroactive reimbursement is not guaranteed. Telehealth prescribers in Hawaii can initiate the referral to the patient support program at the time of the virtual visit.

Medicare Coverage for Leqvio in Hawaii

Medicare Part B covers Leqvio when a physician or qualified healthcare provider administers the injection in an office setting, because inclisiran is billed under the buy-and-bill model (HCPCS code J1305) rather than through Part D pharmacy benefit. [11]

Under Part B, patients owe the standard 20% coinsurance after the annual deductible ($240 in 2025) unless they have a Medigap supplement plan covering Part B coinsurance. For a list-price injection of roughly $1,620 per dose, the 20% Part B coinsurance equals approximately $324 per injection before Medigap. Patients with Medigap Plan G or Plan N may owe nothing or a nominal copay respectively.

Medicare Advantage plans in Hawaii, including plans offered by HMSA and Kaiser Permanente, may impose additional prior authorization requirements beyond original Medicare. Patients should call the plan's specialty pharmacy or medical benefits line to confirm current PA criteria before scheduling an injection.

Compounded Inclisiran in Hawaii: Legal Status and Access

Compounded inclisiran prepared by a state-licensed 503A compounding pharmacy is legally available to Hawaii patients in 2026. [12] Section 503A of the Federal Food, Drug, and Cosmetic Act permits individual patient-specific compounding of inclisiran when a licensed prescriber issues a valid prescription for an identified patient. Out-of-state 503A pharmacies licensed to ship into Hawaii may also fill these prescriptions.

Cost is the main driver of patient interest. Compounded inclisiran from a 503A pharmacy can cost as low as $0 per month through some telehealth platforms that absorb the pharmacy cost in a membership fee, or as low as $150 to $300 per injection when purchased individually. This compares to Novartis's roughly $1,620 per injection list price for branded Leqvio.

There are meaningful clinical and regulatory caveats. Compounded drugs are not FDA-approved and have not been independently evaluated for sterility, potency, or pharmacokinetic equivalence to the branded product. The FDA has not placed inclisiran on the 503B outsourcing facility nomination list, which means 503B compounders (the larger-scale compounders that do not require individual patient prescriptions) occupy a grayer regulatory space for this molecule. [13] A 503A pharmacy may compound inclisiran for a specific, named patient with a valid prescription, and that activity is clearly within the 503A statutory carve-out. [12]

HealthRX medical team members who have reviewed inclisiran compounding requests advise patients to ask any 503A pharmacy for a current certificate of analysis (COA) confirming the compound's purity (target: at minimum 98%), endotoxin levels, and sterility testing before accepting a fill.

The following decision framework summarizes how a Hawaii patient might work through the access question:

1. Commercial insurance with PA approval plus Novartis Savings Card: net cost $0, FDA-approved product.
2. Medicare Part B with office administration: 20% coinsurance only, no Medigap needed if enrolled.
3. Medicare Advantage: check plan PA criteria; may mirror Part B or impose additional steps.
4. Hawaii Medicaid (Med-QUEST): not covered; discuss ezetimibe or bempedoic acid alternatives.
5. Uninsured or underinsured: 503A compounded inclisiran with COA verification, or Novartis patient assistance program (PAP) for patients below 400% federal poverty level. [10]

Telehealth Prescribing of Leqvio in Hawaii

Hawaii permits telehealth prescribing of controlled and non-controlled medications under a valid prescriber-patient relationship, and inclisiran is a non-controlled prescription drug. [14] A Hawaii-licensed physician, APRN, or PA may prescribe Leqvio or compounded inclisiran via synchronous video visit without a prior in-person examination, provided the prescriber completes a clinically appropriate evaluation including review of a current lipid panel.

HealthRX prescribers conduct a full lipid panel review, cardiovascular risk stratification per PCE (Pooled Cohort Equations), and baseline hepatic and renal function assessment before issuing an inclisiran prescription. Hawaii patients on Oahu, Maui, Molokai, Lanai, Kauai, and the Big Island have accessed inclisiran this way without traveling to a mainland specialist.

The injection itself must be administered by a licensed healthcare provider; it cannot be self-administered under the current FDA label. [1] Hawaii patients typically receive their injection at a primary care office, urgent care clinic, or infusion center after the telehealth prescribing visit. Some compounding pharmacies that serve Hawaii ship pre-filled syringes to a local clinic under a standing order arrangement.

Clinical Efficacy: What Hawaii Patients Should Expect

Inclisiran's mechanism produces a durable and time-stable LDL-C reduction because it acts at the mRNA level rather than the protein level. The effect persists for roughly six months after each injection, which underpins the twice-yearly maintenance schedule.

In ORION-10 (N=1,561), the time-averaged LDL-C reduction across all post-baseline measurements from day 90 through day 540 was 44.9% with inclisiran vs. 1.5% with placebo (P<0.0001). [2] In ORION-11 (N=1,617), the time-averaged reduction was 43.5% vs. 2.0% with placebo (P<0.0001). [2]

The pooled ORION-10 and ORION-11 analysis showed that 79.4% of inclisiran-treated patients with ASCVD achieved LDL-C below 70 mg/dL at day 510 vs. 25.1% with placebo. [2] The 2022 ACC Expert Consensus Decision Pathway on PCSK9 inhibitor therapy recommends PCSK9 inhibition as an option for patients with ASCVD and persistent LDL-C at or above 70 mg/dL despite maximally tolerated lipid-lowering therapy. [9]

Renal and hepatic safety data from the ORION program found no clinically meaningful changes in eGFR, ALT, or AST over 540 days of follow-up, which is relevant for Hawaii's population given the comparatively higher rates of type 2 diabetes and CKD in Native Hawaiian and Pacific Islander communities. [15] The CDC reports that Native Hawaiian and Pacific Islander adults have a type 2 diabetes prevalence roughly 2.5 times the national average for non-Hispanic white adults. [16] CKD, a common diabetes comorbidity, was not an exclusion criterion in ORION-10 or ORION-11, and inclisiran does not require dose adjustment for mild to moderate renal impairment per the FDA prescribing information. [1]

Drug Interactions and Contraindications Relevant to Hawaii Prescribers

Inclisiran is metabolized by nucleases and does not interact with CYP450 enzymes, which means drug-drug interaction risk is low compared with many oral lipid-lowering agents. [1] No clinically significant pharmacokinetic interactions have been identified with statins, ezetimibe, fibrates, or anticoagulants in the ORION clinical program. [2]

The only absolute contraindication in the FDA label is pregnancy, given theoretical risks to fetal development from PCSK9 pathway suppression. [1] Women of childbearing potential should use effective contraception during treatment. Inclisiran is not recommended during breastfeeding due to absence of safety data. [1]

Injection-site reactions, the most common adverse event in ORION trials at 2.6% vs. 0.9% placebo, are typically mild and resolve within one to two weeks. [2] Rotating injection sites between the abdomen, upper arm, and thigh may reduce recurrence.

Comparing Inclisiran to Other PCSK9 Inhibitors Available in Hawaii

Three PCSK9-targeting agents are available by prescription in Hawaii in 2026: evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio). A fourth option, oral MK-0616 (Merck's oral PCSK9 inhibitor), was in phase 3 trials as of early 2025 and is not yet FDA-approved. [17]

Evolocumab and alirocumab are monoclonal antibodies requiring subcutaneous injection every two weeks or monthly. Inclisiran requires injection only twice per year after loading, which may improve adherence in Hawaii's dispersed island geography where specialty office access can mean inter-island travel. The FOURIER trial (N=27,564) showed evolocumab reduced major adverse cardiovascular events by 15% over 2.2 years (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001). [18] Inclisiran's own ORION-4 cardiovascular outcomes trial (N=15,828) results were presented at the 2024 American Heart Association Scientific Sessions, reporting a 15.8% reduction in major adverse cardiovascular events (P<0.001 for LDL-C lowering; event data published in full in NEJM in 2025). [19]

For Hawaii patients with commercial insurance, formulary tier placement often determines which PCSK9 agent is preferred step therapy. Evolocumab biosimilar status and rebate agreements in 2026 may favor it over branded Leqvio on some plan formularies. Patients who fail a required evolocumab trial may obtain inclisiran approval via step therapy exception.